Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy-Reference-Cited by-同舟云学术

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

Published:2016-10 Issue:2 Volume:167 Page:397-404.e9
ISSN:0092-8674
Container-title:Cell
language:en
Short-container-title:Cell

Author:

Gao Jianjun,Shi Lewis Zhichang,Zhao Hao,Chen Jianfeng,Xiong Liangwen,He Qiuming,Chen Tenghui,Roszik Jason,Bernatchez Chantale,Woodman Scott E.,Chen Pei-Ling,Hwu Patrick,Allison James P.,Futreal Andrew,Wargo Jennifer A.,Sharma Padmanee

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference40 articles.

1. Expression and function of CTLA-4 in Th1 and Th2 cells;Alegre;J. Immunol.,1998

2. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer;Borghaei;N. Engl. J. Med.,2015

3. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues;Chen;Proc. Natl. Acad. Sci. USA,2009

4. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis;Chin;Mol. Cell. Biol.,1997

5. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples;Cibulskis;Nat. Biotechnol.,2013

Cited by 1051 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for breast cancer: New strategies to enhance the patient selection and overcome therapeutic resistance;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Mechanisms of resistance to immunotherapy;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

3. Treatment options for tumor progression after initial immunotherapy in advanced non-small cell lung cancer: A real-world study;Neoplasia;2024-11

4. Syndecan-1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD1 checkpoint immunotherapy;Science Advances;2024-09-13

5. Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors;Cancer Immunology, Immunotherapy;2024-09-13